Published studies and data from multiple clinical trials support the concomitant blockade of HER2/ER and CDK4/6–Cyclin D–Rb pathways as an effective chemotherapy-free treatment opportunity for improved outcomes and management in HER2+/ER+ BC patients [30,31,106,122]. The gene discussed is ESR1; the disease is breast cancer.